Therapy of steroid-resistant inflammatory bowel disease

Digestion

Volumn 86, Issue SUPPL. 1, 2012, Pages 11-15

  Manz, Michael ^a   Vavricka, Stephan R ^b,c   Wanner, Roger ^c   Lakatos, Peter L ^e   Rogler, Gerhard ^c   Frei, Pascal ^c   Safroneeva, Ekaterina ^f   Schoepfer, Alain M ^d  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Division of Gastroenterology and Hepatology   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e SEMMELWEIS UNIVERSITY   (Hungary)

^f UNIVERSITY OF BERN   (Switzerland)

Author keywords

Crohn's disease; Steroid resistant inflammatory bowel disease; Ulcerative colitis

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID; AZATHIOPRINE; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; CYCLOSPORIN; CYCLOSPORIN A; HYDROCORTISONE; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; TACROLIMUS;

ARTICLE; CORTICOSTEROID THERAPY; CROHN DISEASE; DRUG EFFICACY; ENTERITIS; HUMAN; LONG TERM CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REMISSION; ULCERATIVE COLITIS;

ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG RESISTANCE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; PREDNISOLONE;

EID: 84867553700     PISSN: 00122823     EISSN: 14219867     Source Type: Journal    
DOI: 10.1159/000341952     Document Type: Article

References (35)

1. Creed TJ, Probert CS: Review article: steroid resistance in inflammatory bowel disease-mechanisms and therapeutic strategies. Aliment Pharmacol Ther 2007; 25:111-122.
2. Mowat C, Cole A, Windsor A, Ahmad T, Ar-nott I, Driscoll R, et al: Guidelines for the management of inflammatory bowel disease in adults. Gut 2011; 60:571-607.
3. Baron JH, Connell AM, Kanaghinis TG, Lennard-Jones JE, Jones AF: Out-patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone. Br Med J 1962; 2: 441-443.
4. Dignass A, Van Assche G, Lindsay JO, Le-mann M, Soderholm J, Colombel JF, et al: The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohn Colitis 2010; 4:28-62.
5. Lichtenstein GR, Abreu MT, Cohen R, Tre-maine W: American Gastroenterological Association Institute technical review on corti-costeroids, immunomodulators, and inflix-imab in inflammatory bowel disease. Gastroenterolog y 2006; 130: 940-987.
6. Munkholm P, Langholz E, Davidsen M, Binder V: Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994; 35: 360-362.
7. Steinhart AH, Ewe K, Griffiths AM, Modi-gliani R, Thomsen OO: Corticosteroids for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2003:CD000301.
8. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ: The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121: 255-260.
9. Barnes PJ, Adcock IM: Glucocorticoid resistance in inflammatory diseases. Lancet 2009; 373: 1905-1917.
10. D'Haens G, Sandborn WJ, Feagan BG, Ge-boes K, Hanauer SB, Irvine EJ, et al: A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007; 132: 763-786.
11. Caprilli R, Gassull MA, Escher JC, Moser G, Munkholm P, Forbes A, et al: European evidence-based consensus on the diagnosis and management of Crohn's disease: special situations. Gut 2006; 55(suppl 1):i36-58.
12. Travis SP, Stange E F, Lemann M, Oresland T, Chowers Y, Forbes A, et al: European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006; 55(suppl 1):i16-i35.
13. Stange EF, Travis SP, Vermeire S, Beglinger C, Kupcinkas L, Geboes K, et al: European evidence-based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut 2006; 55(suppl 1):i1-i5.
14. Pearson DC, May GR, Fick GH, Sutherland LR: Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995; 123: 132-142.
15. Prefontaine E, Macdonald JK, Sutherland LR: Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2010;CD000545.
16. Pearson DC, May GR, Fick G, Sutherland LR: Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev 2000;CD000067.
17. Prefontaine E, Sutherland LR, Macdonald JK, Cepoiu M: Azathioprine or 6-mercapto-purine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009;CD000067.
18. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al: Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-1395.
19. Chouchana L, Narjoz C, Beaune P, Loriot M A, Roblin X: Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2012; 35: 15-36.
20. Alfadhli AA, McDonald JW, Feagan BG: Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst Rev 2005;CD003459.
21. Patel V, Macdonald JK, McDonald JW, Chande N: Methotrexate for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009;CD006884.
22. Taylor KM, Irving PM: Optimization of conventional therapy in patients with IBD. Nat Rev Gastroenterol Hepatol 2011; 8:646-656.
23. Lemann M, Mary JY, Duclos B, Veyrac M, Dupas JL, Delchier JC, et al: Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-control led trial. Gastroenterology 2006; 130: 1054-1061.
24. Hanauer SB, Sandborn WJ, Rutgeerts P, Fe-dorak RN, Lukas M, Macintosh D, Panac-cione R, Wolf D, Pollack P, llack PF: Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323-333.
25. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pol lack PF: Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastro-enterology 2007; 132: 52-65.
26. Schreiber S, Khaliq-Kareemi M, Lawrance IC, Ostergaard Thomson O, Hanauer SB, McColm J, Bloomfield R, Sandborn W: Maintenance therapy with certolizumab pe-gol for Crohn's disease. N Engl J Med 2007; 357: 239-250.
27. Stange EF, Travis SP, Vermeire S, Reinisch W, Geboes K, Barakauskiene A, et al: European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohn Colitis 2008; 2: 1-23.
28. Manz M, Michetti P, Seibold F, Rogler G, Beglinger C: Treatment algorithm for moderate to severe ulcerative colitis. Swiss Med Wkly 2011; 141:w13235.
29. Travis SP, Stange E F, Lemann M, Oresland T, Bemelman WA, Chowers Y, et al: European evidence-based consensus on the management of ulcerative colitis: current management. J Crohn Colitis 2008; 2: 24-62.
30. McDonald JW, Macdonald JK: Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2007;CD000478.
31. Rutgeerts P, Sandborn WJ, Feagan BG, Rein-isch W, Olson A, Johanns J, et al: Infliximab for induction and maintenance therapy for u lcerative colitis. N Engl J Med 2005; 353: 2462-2476.
32. Reinisch W, Sandborn WJ, Rutgeerts P, Fea-gan BG, Rachmilewitz D, Hanauer SB, et al: Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and-2 extension studies. Inf lamm Bowel Dis 2012; 18: 201-211.
33. Oussalah A, Evesque L, Laharie D, Roblin X, Boschetti G, Nancey S, et al: A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitaliza-tion. Am J Gastroenterol 2010; 105: 2617-2625.
34. Sandborn WJ, van Assche G, Reinisch W, Colombel JF, D'Haens G, Wolf DC, et al: Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142:257-65 e1-3.
35. Turner D, Walsh CM, Steinhart AH, Griffiths AM: Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 2007; 5:103-110.